What therapies are on the horizon for HER2 positive breast cancer?

What therapies are on the horizon for HER2 positive breast cancer? Expert Rev Anticancer Ther. 2019 Aug 26;: Authors: Viale G, Morganti S, Ferraro E, Zagami P, Marra A, Curigliano G Abstract INTRODUCTION: Despite dramatic improvements in survival achieved with currently available anti-HER2 agents, HER2 positive metastatic breast cancer remains an almost invariably deadly disease, with primary or acquired resistance to HER2 directed agents developing during course treatment. Many efforts are focused on identifying new agents that may more effectively inhibit HER2 signaling and on possible combination strategies. Areas covered: This review summarizes the landscape of drugs under development for HER2 positive metastatic breast cancer, as antibody-drug conjugates, monoclonal anti-HER2 antibodies, bispecific antibodies, or novel tyrosine kinase inhibitors. Moreover, available data for possible combination of anti-HER2 drugs and different agents, as immunotherapy, PI3K/mTOR inhibitors, CDK4/6 inhibitors currently under evaluation are reviewed. These strategies may overcome mechanisms of resistance and further improve patient outcomes. Expert opinion: Identification of valuable predictive biomarkers is needed to better inform choice of treatment sequence for the individual patient and limit the financial toxicity of these agents. PMID: 31448640 [PubMed - as supplied by publisher]
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research